

CGA15324/Lambda-cyhalothrin
CGA15324/Lambda-cyhalothrin EC (A13735F) - *Salmonella*
***Typhimurium* and *Escherichia Coli* Reverse Mutation Assay**
Final Report

TEST GUIDELINE(S): OECD 471 (2020)

AUTHOR(S): Dr. Steffi Chang

COMPLETION DATE: 07 July 2021

PERFORMING LABORATORY: ICCR-Roßdorf GmbH
In den Leppsteinswiesen 19
64380 Rossdorf, Germany

LABORATORY PROJECT ID: Report Number: 2165900
Study Number: 2165900
Task Number: TK0588457

SPONSOR(S): Syngenta Ltd.
Jealott's Hill International Research Centre
Bracknell, Berkshire RG42 6EY, United Kingdom

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo
SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº
9.279/96, artigo 9º da Lei 10.603/02.
É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles
descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

STATEMENT OF DATA CONFIDENTIALITY CLAIMS

The Following Statement Applies To The United States of America:

STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS UNDER SPECIFIED FIFRA PROVISIONS

No claim of confidentiality, on any basis whatsoever, is made for any information contained in this document. I acknowledge that information not designated as within the scope of FIFRA sec. 10(d)(1)(A), (B), or (C) and which pertains to a registered or previously registered pesticide is not entitled to confidential treatment and may be released to the public, subject to the provisions regarding disclosure to multinational entities under FIFRA 10(g).

Company: Syngenta Crop Protection, LLC
410 Swing Road
Post Office Box 18300
Greensboro, NC 27419-8300 USA

Submitter: _____

Date: _____

Syngenta is the owner of this information and data. Syngenta has submitted this material to the United States Environmental Protection Agency specifically under the provisions contained in FIFRA as amended and, hereby, consents to use and disclosure of this material by EPA according to FIFRA. In submitting this material to EPA according to method and format requirements contained in PR Notice 2011-3, we do not waive any protection or right involving this material that would have been claimed by the company if this material had not been submitted to the EPA, nor do we waive any protection or right provided under FIFRA Section 3 (concerning data exclusivity and data compensation) or FIFRA Section 10(g) (prohibiting disclosure to foreign and multinational pesticide companies or their agents).

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.609/98, artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT[®]

This study performed in the test facility of ICCR-Rosßdorf GmbH, In den Leppsteinswiesen 19, 64380 Rosßdorf, Germany was conducted in compliance with Good Laboratory Practice Regulations:

Chemikaliengesetz (Chemicals Act) of the Federal Republic of Germany, "Anhang 1" (Annex 1), in its currently valid version

OECD Principles of Good Laboratory Practice, (as revised in 1997), ENV/MC/CHEM(98)17

EC Commission Directive 2004/10/EC

These procedures are compatible with Good Laboratory Practice regulations specified by regulatory authorities throughout the European Community, the United States (EPA and FDA), and Japan (MHW, MAFF, and METI), and other countries that are signatories to the OECD Mutual Acceptance of Data Agreement.

There were no circumstances that may have affected the quality or integrity of the study.

Dr. Steffi Chang
Study Director Bacterial Systems


Date: 07 July 2021

Performing Laboratory:
ICCR-Rosßdorf GmbH
In den Leppsteinswiesen 19
64380 Rosßdorf, Germany

To be completed for USA EPA submission only:
Representative of Submitter/Sponsor:

Date

Submitter/Sponsor: Syngenta Crop Protection, LLC
410 Swing Road
Post Office Box 18300
Greensboro, NC 27419-8300 USA

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.379/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.
É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

Report Number: 2165900

Page 3 of 39

FLAGGING STATEMENT

This page is intentionally left blank. It will be replaced by an appropriate Flagging statement by the Sponsor.

CONFIDENTIAL
Property of Syngenta
syngenta®

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 10.603/02, artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

QUALITY ASSURANCE STATEMENT

ICCR Study Number: 2165900
Test substance: CGA15324/lambda-cyhalothrin EC (A13735F)
Study director: Dr. Steffi Chang
Study Title: CGA15324/Lambda-cyhalothrin EC (A13735F) -
Salmonella Typhimurium and
Escherichia Coli Reverse Mutation Assay

Study based activities at the Test Facility ICCR-Roßdorf GmbH were audited and inspected. The details of these audits and inspections are given below.

Type of Inspection	Date(s) of Inspection	Date Reporting to Study Director, Test Facility Management
Study Plan Verification	30 April 2021	30 April 2021
Study – based Test Item preparation	05 May 2021	05 May 2021
Report Audit	24 June 2021	25 June 2021

General facilities and activities where this study was conducted were inspected on an annual basis and results are reported to the relevant responsible person and Management.

The statement is to confirm, that this report reflects the raw data.

S. Ebert

07 July 2021

Sabine Ebert

Date

Quality Assurance Auditor
ICCR-Roßdorf GmbH

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

Report Number: 2165900

Page 5 of 39

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

PROJECT STAFF SIGNATURE

Study Director

Dr. Steffi Chang



.....
Date: 07 July 2021

CONFIDENTIAL
Property of Syngenta
syngenta[®]

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo **SEGREDO DE NEGÓCIO** e **SEGREDO DE INDÚSTRIA**, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/06 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

Report Number: 2165900

Page 6 of 39

Qualquer divulgação não autorizada e divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

GENERAL INFORMATION

Contributors

The following contributed to this report in the capacities indicated:

Name	Title
Dr. Steffi Chang	Study Director
Dr. Markus Schulz	Test Facility Management
Frauke Hermann	Head of Quality Assurance Unit
Carolina Vaccari	Syngenta Study Manager

Study Dates

Study initiation date:	03 May 2021
Experimental start date:	05 May 2021
Experimental completion date:	25 May 2021

Deviations from the Guidelines

None

Retention of Samples

None

Performing Laboratory Test Substance Reference Number

S 2156011

Other

ICCR-Roßdorf GmbH will archive:

Records and documentation relating to this study will be maintained in the archives of ICCR-Roßdorf GmbH for a period of 4 years from the date on which the Study Director signs the final report. This will include electronic and paper raw data, and report that support the reconstruction of the study.

At termination of the aforementioned period, the records and documentation will be transferred to the GLP compliant Archive of Rhenus Archiv Services GmbH, Frankfurt am Main for further archiving up to a total archiving period of 15 years.

A sample of the test substance will not be archived.

ICCR Roßdorf GmbH will retain in its archive a copy of the study plan and final report, and any amendments indefinitely.

Deviations from the study plan

There were no deviations (unplanned changes) from the study plan.

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.609/98, artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

Distribution of the report

Sponsor 2 × electronic copy (1 × pdf-file, 1 × Word-file)
Study Director 1 × (original)

CONFIDENTIAL
Property of Syngenta
syngenta®

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo **SEGREDO DE NEGÓCIO** e **SEGREDO DE INDÚSTRIA**, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 10.603/02, artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

TABLE OF CONTENTS

STATEMENT OF DATA CONFIDENTIALITY CLAIMS	2
GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT	3
FLAGGING STATEMENT	4
QUALITY ASSURANCE STATEMENT	5
PROJECT STAFF SIGNATURE	6
GENERAL INFORMATION	7
TABLE OF CONTENTS	9
1.0 EXECUTIVE SUMMARY	11
1.1 Study Design	11
1.2 Results	11
1.3 Conclusion.....	11
2.0 INTRODUCTION	12
2.1 Purpose.....	12
2.2 Test Guideline(s).....	12
3.0 MATERIALS AND METHODS	13
3.1 Test Substance.....	13
3.2 Controls	14
3.2.1 Negative controls	14
3.2.2 Positive control substances	14
3.3 Experimental Design.....	15
3.3.1 Characterisation of the <i>Salmonella typhimurium</i> and <i>E. coli</i> strains	15
3.3.2 Storage.....	16
3.3.3 Precultures.....	16
3.3.4 Selective agar	16
3.3.5 Overlay agar	16
3.4 Mammalian Microsomal Fraction S9 Mix.....	16
3.4.1 S9 (Preparation by ICCR-Roßdorf GmbH).....	16
3.4.2 S9 mix	17
3.5 Pre-Experiment for Cytotoxicity.....	17
3.6 Concentration Selection	17
3.7 Experimental Performance.....	18
3.8 Data Evaluation.....	18

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.609/98 e pelo artigo 9º da Lei 10.603/02.

Report Number: 2165900

Page 9 of 39

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

3.8.1	Data recording	18
3.8.2	Acceptability of the assay	19
3.8.3	Evaluation of results.....	19
3.8.4	Biometry.....	19
3.9	Major Computerized System.....	19
4.0	RESULTS AND DISCUSSION	20
5.0	CONCLUSIONS	21
6.0	REFERENCES	22
TABLES SECTION		23
TABLE 1	Summary of Results Pre-Experiment/Experiment I.....	24
TABLE 2	Summary of Results Experiment II.....	25
TABLE 3	Pre-Experiment and Experiment I: 2165900 VV Plate Incorporation Without Metabolic Activation.....	26
TABLE 4	Pre-Experiment and Experiment I: 2165900 VV Plate Incorporation With Metabolic Activation.....	28
TABLE 5	Experiment II: 2165900 HV2 Pre Incubation Without Metabolic Activation.....	30
TABLE 6	Experiment II: 2165900 HV2 Pre Incubation With Metabolic Activation.....	32
APPENDICES SECTION		34
APPENDIX 1	Historical Control Data	35
APPENDIX 2	Copy of GLP Certificate	36
APPENDIX 3	Certificate of S9	37
APPENDIX 4	Certificate of Analysis.....	39

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo
 SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N°
 9.279/96, artigo 9° da Lei 10.603/02.

Report Number: 2165900

Page 10 of 39

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles
 descritos no parágrafo 2° do artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

1.0 EXECUTIVE SUMMARY

1.1 Study Design

This study was performed to investigate the potential of CGA15324/lambda-cyhalothrin EC (A13735F) to induce gene mutations in the plate incorporation test (Experiment I) and the pre-incubation test (Experiment II) using the *Salmonella typhimurium* (*S. typhimurium*) strains TA1535, TA1537, TA98, and TA100, and the *Escherichia coli* (*E. coli*) strains WP2 *uvrA* (pKM101) and WP2 (pKM101).

1.2 Results

The plates incubated with the test substance showed normal background growth up to the maximal concentration of 5000 µg/plate with and without S9 mix in all strains used.

Cytotoxic effects, evident as a reduction in the number of revertants (below the indication factor of 0.5), occurred in Experiment I in strain WP2 (pKM101) in the absence of S9 mix and in strains TA1535 and TA100 in the presence of S9 mix, and in Experiment II in strain TA1537 in the absence of S9 mix and in strains TA98, TA100 and WP2 (pKM101) in the presence and absence of S9 mix.

No relevant increase in revertant colony numbers of any of the six tester strains was observed following treatment with CGA15324/lambda-cyhalothrin EC (A13735F) at any concentration, neither in the presence nor absence of metabolic activation (S9 mix). There was also no observed tendency of higher mutation rates with increasing concentrations in the range below the generally acknowledged border of biological relevance.

Appropriate reference mutagens were used as positive controls, which showed a distinct increase of induced revertant colonies consistent with the laboratory's historical control data demonstrated the sensitivity of the test system and the efficacy of the S9 mix. Each batch of S9 was also tested with 2 pro-mutagens, benzo(a)pyrene and 2-aminoanthracene.

1.3 Conclusion

In conclusion, it can be stated that during the described mutagenicity tests and under the experimental conditions reported, CGA15324/lambda-cyhalothrin EC (A13735F) did not induce gene mutations by base pair changes or frameshifts in the genome of the strains used.

Therefore, CGA15324/lambda-cyhalothrin EC (A13735F) is considered to be non-mutagenic in the *Salmonella typhimurium* and *Escherichia coli* reverse mutation assay.

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N° 9.609/98, e pelo artigo 9° da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2° do artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

2.0 INTRODUCTION

2.1 Purpose

These experiments were performed to assess the potential of the test substance to induce gene mutations by means of the *S. typhimurium* and *E. coli* reverse mutation assay. Experiment I was performed as a plate incorporation assay. Since a negative result was obtained in this experiment, Experiment II was performed as a pre-incubation assay.

The most widely used assays for detecting gene mutations are those using bacteria (1). They are relatively simple and rapid to perform, and give reliable data on the ability of an agent to interact with DNA and produce mutations.

Reverse mutation assays determine the frequency with which an agent reverses or suppresses the effect of the forward mutation. The genetic target presented to an agent is therefore small, specific and selective. Several bacterial strains, or a single strain with multiple markers are necessary to assure reliable detection of mutagens that may be specific to one tester strain or locus. The reversion of bacteria from growth-dependence on a particular amino acid to growth in the absence of that amino acid (reversion from auxotrophy to prototrophy) is the most widely used marker.

The *S. typhimurium* histidine (his) and the *E. coli* tryptophan (trp) reversion system measures his⁻ → his⁺ and trp⁻ → trp⁺ reversions, respectively. The *S. typhimurium* and *E. coli* strains are constructed to differentiate between base pair (TA1535, TA100, WP2 *uvrA* (pKM101), and WP2 (pKM101)) and frameshift (TA1537, TA98) mutations.

According to the direct plate incorporation and pre-incubation method the bacteria are exposed to the test substance with and without metabolic activation and plated on selective medium. After a suitable period of incubation, revertant colonies are counted.

To establish a concentration response effect at least six concentrations with adequately spaced intervals were tested. The maximum concentration was 5000 µg/plate.

To validate the test, reference mutagens were tested in parallel to the test substance.

2.2 Test Guideline(s)

This study followed the procedures indicated by the following internationally accepted guideline and recommendations:

“Ninth Addendum to OECD Guidelines for Testing of Chemicals”, Section 4, No. 471:
“Bacterial Reverse Mutation Test”, corrected June 26, 2020

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.609/98 e pelo artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

3.0 MATERIALS AND METHODS

3.1 Test Substance

Information as provided by the Sponsor.

Identification:	CGA15324/lambda-cyhalothrin EC (A13735F)
Batch:	SMU1BL001
Content of Profenofos:	27.3% w/w corresponding to 300 g/L
Content of Lambda-Cyhalothrin:	1.37% w/w corresponding to 15.1 g/L
Appearance:	brown liquid
Recertification Date:	28 February 2023
Storage Conditions:	At room temperature
Stability in Solvent:	Not indicated by the Sponsor

The test substance concentrations were not adjusted for the content of CGA15324 or lambda-cyhalothrin.

On the day of the experiment (immediately before use), the test substance was dissolved in dimethylsulfoxide (DMSO, purity > 99%). The solvent was chosen as the most suitable solvent compared to water and ethanol, according to its solubilisation properties and its relative non-toxicity to the bacteria (2).

All formulations were prepared freshly before treatment and used within two hours of preparation. The formulation was assumed to be stable for this period unless specified otherwise by the Sponsor.

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.609/98, artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

3.2 Controls

3.2.1 Negative controls

Concurrent untreated and solvent controls were performed.

3.2.2 Positive control substances

Without metabolic activation

Strains: TA1535, TA100
Name: Sodium azide, (NaN₃)
Supplier: SERVA, 69042 Heidelberg, Germany
Batch No.: STBJ7813
Purity: ≥ 99%
Dissolved in: Deionised water
Concentration: 10 µg/plate

Strains: TA1537, TA98
Name: 4-nitro-o-phenylene-diamine, (4-NOPD)
Supplier: Sigma-Aldrich, 82024 Taufkirchen, Germany
Batch No.: MKBM 5257V
Purity: ≥ 98%
Dissolved in: DMSO (purity >99 %, Fisher Leics LE11 5RG, United Kingdom)
Concentration: 10 µg/plate in strain TA 98, 50 µg/plate in strain TA 1537

Strains: WP2 *uvrA* (pKM101), WP2 (pKM101)
Name: Methyl methane sulfonate, (MMS)
Supplier: Sigma-Aldrich, 82024 Taufkirchen, Germany
Batch No.: MKCL 6261
Purity: ≥ 99%
Dissolved in: Deionised water
Concentration: 2.0 µL/plate

With metabolic activation

Strains: TA1535, TA1537, TA98, TA100, WP2 *uvrA* (pKM101), WP2 (pKM 101)
Name: 2-aminoanthracene, (2-AA)
Supplier: Sigma-Aldrich, 82024 Taufkirchen, Germany
Batch No.: STBG 0630V
Purity: ≥ 96%
Dissolved in: DMSO (purity > 99 %, Fisher Leics LE11 5RG, United Kingdom)
Concentration: 2.5 µg/plate (TA1535, TA1537, TA98, TA100),
10 µg/plate (WP2 *uvrA* (pKM101), WP2 (pKM101))

The stability of the positive control substances in solution is unknown but a mutagenic response in the expected range is sufficient evidence of biological activity.

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N°

Report Number: 2165900

Page 14 of 39

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

3.3 Experimental Design

3.3.1 Characterisation of the *Salmonella typhimurium* and *E. coli* strains

The histidine dependent strains are derived from *S. typhimurium* strain LT2 through mutations in the histidine locus. Additionally, due to the "deep rough" (*rfa*⁻) mutation they possess a faulty lipopolysaccharide envelope which enables substances to penetrate the cell wall more easily. A further mutation causes a reduction in the activity of an excision repair system. The last alteration includes mutational processes in the nitrate reductase and biotin genes produced in a UV-sensitive area of the gene named *uvrB*⁻. In the strains TA98 and TA100 the R-factor plasmid pKM101 carries the ampicillin resistance marker (3).

Strain WP2 (4) and its derivatives all carry the same defect in one of the genes for tryptophan biosynthesis. Tryptophan-independent (*Trp*⁺) mutants (revertants) can arise either by a base change at the site of the original alteration or by a base change elsewhere in the chromosome so that the original defect is suppressed. This second possibility can occur in several different ways so that the system seems capable of detecting all types of mutagen which substitute one base for another. Additionally, the *uvrA* derivative is deficient in the DNA repair process (excisable repair damage). Such a repair-deficient strain may be more readily mutated by agents. The *E. coli* strains WP2 *uvrA* (pKM101) and WP2 (pKM101) are constructed by introduction of the R-factor plasmid pKM101.

When summarized, the mutations of the *S. typhimurium* and *E. coli* strains used in this study can be described as follows:

Strains	Genotype	Type of mutations indicated
<i>Salmonella typhimurium</i>		
TA1537	<i>his C 3076; rfa</i> ⁻ ; <i>uvrB</i> ⁻	frame shift mutations
TA98	<i>his D 3052; rfa</i> ⁻ ; <i>uvrB</i> ⁻ ; R-factor	" "
TA1535	<i>his G 46; rfa</i> ⁻ ; <i>uvrB</i> ⁻	base-pair substitutions
TA100	<i>his G 46; rfa</i> ⁻ ; <i>uvrB</i> ⁻ ; R-factor	" "
<i>Escherichia coli</i>		
WP2 <i>uvrA</i> (pKM101)	<i>trp E 56 uvrA</i> ⁻ ; R-factor	base-pair substitutions and others
WP2 (pKM101)	<i>trp E 56</i> ; R-factor	" "

Regular checking of the properties of the *S. typhimurium* and *E. coli* strains regarding the membrane permeability and ampicillin resistance; UV sensitivity, and amino acid requirement as well as normal spontaneous mutation rates is performed by ICCR-Roßdorf GmbH according to Ames *et al.* (5), Maron and Ames (3), and Mortelmans and Riccio (7). In this way it is ensured that the experimental conditions set down by Ames are fulfilled.

The bacterial strains TA1535, TA1537, TA98, TA100, WP2 *uvrA* (pKM101), and WP2 (pKM101) were obtained from Trinova Biochem GmbH (35394 Gießen, Germany).

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N°

Report Number: 2165900 Artigo 9º da Lei 10.603/02.

Page 15 of 39

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

3.3.2 Storage

The strain cultures were stored as stock cultures in ampoules with nutrient broth + 5 % DMSO (Fisher Leics, LE11 5RG, United Kingdom) in liquid nitrogen.

3.3.3 Precultures

The thawed bacterial suspension was transferred into 250 mL Erlenmeyer flasks containing nutrient medium (50 mL). A solution of ampicillin (50 µL, 25 µg/mL) was added to the strains TA98, TA100, WP2 *uvrA* (pKM101), and WP2 (pKM101). This nutrient medium contains per liter:

8 g Nutrient Broth (MERCK, 64293 Darmstadt, Germany)

5 g NaCl (MERCK, 64293 Darmstadt, Germany)

The bacterial cultures were incubated in a shaking water bath for 4 hours at 37 °C. The optical density of the bacteria was determined by absorption measurement and the obtained values indicated that the bacteria were harvested at the late exponential or early stationary phase (10^8 - 10^9 cells/mL).

3.3.4 Selective agar

Plates with selective agar (without Histidine/Tryptophan) were used.

3.3.5 Overlay agar

The overlay agar contained per litre:

for *Salmonella* strains:

7.0 g Agar Agar*

6.0 g NaCl*

10.5 mg L-Histidine×HCl×H₂O*

12.2 mg Biotin*

for *Escherichia coli* strains:

7.0 g Agar Agar*

6.0 g NaCl*

10.2 mg Tryptophan*

* (MERCK, 64293 Darmstadt, Germany)

Sterilisations were performed at 121 °C in an autoclave.

3.4 Mammalian Microsomal Fraction S9 Mix

The bacteria used in this assay do not possess the enzyme systems which, in mammals, are known to convert promutagens into active DNA damaging metabolites. In order to overcome this major drawback an exogenous metabolic system is added in the form of mammalian microsome enzyme activation mixture.

3.4.1 S9 (Preparation by ICCR-Roßdorf GmbH)

Phenobarbital/β-naphthoflavone induced rat liver S9 was used as the metabolic activation system. The S9 was prepared from male Wistar rats (RjHan:WI; weight approx. 220 – 320 g,

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N° 9.609/98, artigo 9° da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2° do artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

Janvier Labs, 53941 Saint-Berthevin Cedex, France) induced by peroral administration of 80 mg/kg b.w. phenobarbital (Sigma-Aldrich Chemie GmbH, 82024 Taufkirchen, Germany) and by peroral administrations of β -naphthoflavone (Acros Organics, 2440 Geel, Belgium) each, on three consecutive days. The livers were prepared 24 hours after the last treatment. The S9 fractions were produced by dilution of the liver homogenate with a KCl solution (1+3 parts) followed by centrifugation at 9000 g. Aliquots of the supernatant were frozen and stored in ampoules at -80°C . Small numbers of the ampoules can be kept at -20°C for up to one week. Each batch of S9 mix is routinely tested with 2-aminoanthracene as well as benzo[a]pyrene (Appendix 3).

The protein concentration in the S9 preparation was 31.2 mg/mL (lot no. 291020D, recertified 10 May 2021) in both experiments.

3.4.2 S9 mix

Before the experiment an appropriate quantity of S9 supernatant was thawed and mixed with S9 cofactor solution. The amount of S9 supernatant was 10% v/v in the S9 mix. Cofactors were added to the S9 mix to reach the following concentrations in the S9 mix:

8 mM MgCl_2
33 mM KCl
5 mM Glucose-6-phosphate
4 mM NADP

in 100 mM sodium-ortho-phosphate-buffer, pH 7.4.

During the experiment the S9 mix was stored in an ice bath. The S9 mix preparation was performed according to Ames *et al.* (5).

3.5 Pre-Experiment for Cytotoxicity

To evaluate the cytotoxicity of the test substance a pre-experiment was performed with all strains. Eight concentrations were tested for cytotoxicity and mutation induction each with three replicate plates. The experimental conditions in this pre-experiment are described in section 3.7 (plate incorporation test).

Cytotoxicity of the test substance results in a reduction in the number of spontaneous revertants (below a factor of 0.5) or a clearing of the bacterial background lawn.

The pre-experiment is reported as the Main Experiment I since the criteria mentioned in Section 3.8.2 Acceptability of the Assay were met.

3.6 Concentration Selection

In the pre-experiment the concentration range of the test substance was 3 - 5000 $\mu\text{g}/\text{plate}$. The pre-experiment is reported as Experiment I. Since minor cytotoxic effects were

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N°

Report Number: 2165900

Page 17 of 39

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

observed in Experiment I, six concentrations were tested in all strains without S9 mix and seven concentrations in all strains with S9 mix. 5000 µg/plate was chosen as the maximal concentration in Experiment II.

The concentration range included two logarithmic decades. The following concentrations were tested in Experiment II:

All strains without S9 mix: 33; 100; 333; 1000; 2500; and 5000 µg/plate
All strains with S9 mix: 10; 33; 100; 333; 1000; 2500; and 5000 µg/plate

3.7 Experimental Performance

For each strain and concentration including the controls, three plates were used.

The following materials were mixed in a test tube and poured onto the selective agar plates:

- 100 µL Test solution at each concentration, solvent (negative control) or reference mutagen solution (positive control),
- 500 µL S9 mix (for test with metabolic activation) or S9 mix substitution buffer* (for test without metabolic activation),
- 100 µL Bacteria suspension (cf. test system, pre-culture of the strains; OD = 1.0 - 1.2; wavelength = 500 nm; approx. 8×10^8 cells/mL),
- 2000 µL Overlay agar

For the pre-incubation method test solution (100 µL) (solvent or reference mutagen solution (positive control)), S9 mix / S9 mix substitution buffer* (500 µL) and bacteria suspension (100 µL) were mixed in a test tube and incubated at $37 \text{ C} \pm 1.5^\circ \text{ C}$ for 60 minutes. After pre-incubation overlay agar (2.0 mL, 45° C) was added to each tube. The mixture was poured on selective agar plates.

After solidification the plates were incubated upside down for 72 hours at $37 \text{ C} \pm 1.5^\circ \text{ C}$ in the dark, plates were then stored at 4° C until counted (6).

In parallel to each test a sterile control of the test substance was performed and documented in the raw data. Therefore, stock solution (100 µL) and S9 mix / S9 mix substitution buffer* (500 µL) were mixed with overlay agar (2.0 mL) and poured on minimal agar plates.

* Substitution buffer: 7 parts of the 100 mM sodium-ortho-phosphate-buffer pH 7.4 with 3 parts of KCl solution 0.15 M

3.8 Data Evaluation

3.8.1 Data recording

The colonies were counted using a Petri Viewer with the software program Ames Study Manager (see section 3.9, Major computerized systems). The evaluation unit was connected to a PC with printer to print out the individual values, the means from the plates for each

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N° 9.609/98 e pelo artigo 9° da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2° do artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

concentration together with standard deviations and enhancement factors as compared to the spontaneous reversion rates (see tables of results). The print outs are kept with the raw data. Due to precipitation of the test item some test groups were scored manually (as indicated on data tables).

3.8.2 Acceptability of the assay

The *Salmonella typhimurium* and *Escherichia coli* reverse mutation assay is considered acceptable if it meets the following criteria:

- regular background growth in the negative and solvent control
- the spontaneous reversion rates in the negative and solvent control are in the range of the historical data
- the positive control substances should produce an increase above the threshold of twofold (strains TA 98, TA 100, WP2 uvrA (pKM101, and WP2 (pKM101))) or threefold (strains TA 1535 and TA 1537) the revertant colony count of the corresponding solvent control;
- a minimum of five analysable concentrations should be present with at least four showing no signs of toxic effects, evident as a reduction in the number of revertants below the indication factor of 0.5.

3.8.3 Evaluation of results

A test substance is considered as a mutagen if a biologically relevant increase in the number of revertants of twofold or above (strains TA 98, TA 100, WP2 uvrA (pKM101), and WP2 (pKM101)) or of threefold or above (strains TA 1535 and TA 1537) the spontaneous mutation rate of the corresponding solvent control is observed.

A concentration dependent increase is considered biologically relevant if the threshold is reached or exceeded at more than one concentration (6).

An increase of revertant colonies equal or above the threshold at only one concentration is judged as biologically relevant if reproduced in an independent second experiment.

A concentration dependent increase in the number of revertant colonies below the threshold is regarded as an indication of a mutagenic potential if reproduced in an independent second experiment. However, whenever the colony counts remain within the historical range of negative and solvent controls, such an increase is not considered biologically relevant.

3.8.4 Biometry

According to the OECD guideline 471, a statistical analysis of the data is not mandatory.

3.9 Major Computerized System

Petri Viewer Sorcerer Colony Counter 3.0 (Instem, Suffolk IP33 3TA, UK) with the software program Ames Study Manager (v1.24) and Ames Archive Manager (v1.01).

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N° 9.609/98, artigo 9° da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2° do artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

4.0 RESULTS AND DISCUSSION

The test substance, CGA15324/lambda-cyhalothrin EC (A13735F), was assessed for its potential to induce gene mutations in the plate incorporation test (Experiment I) and the pre-incubation test (Experiment II) using *S. typhimurium* strains TA1535, TA1537, TA98, and TA100, and the *E. coli* strains WP2 (pKM101) and WP2 *uvrA* (pKM101).

In the pre-experiment the concentration range of the test substance was 3 - 5000 µg/plate. The pre-experiment is reported as Experiment I. Since minor cytotoxic effects were observed in Experiment I, six concentrations were tested in all strains without S9 mix and seven concentrations in all strains with S9 mix. 5000 µg/plate was chosen as the maximal concentration in Experiment II. This is the maximum concentration recommended in the OECD test guideline.

The assay was performed with and without liver microsomal activation. Each concentration, including the controls, was tested in triplicate. The concentration range included two logarithmic decades. The test substance was tested at the following concentrations:

Pre-Experiment/Experiment I: 3; 10; 33; 100; 333; 1000; 2500; and 5000 µg/plate

Experiment II:

All strains without S9 mix: 33; 100; 333; 1000; 2500; and 5000 µg/plate

All strains with S9 mix: 10; 33; 100; 333; 1000; 2500; and 5000 µg/plate

The test substance precipitated in the overlay agar in the test tubes from 1000 to 5000 µg/plate. Precipitation of the test item in the overlay agar on the incubated agar plates was observed at 5000 µg/plate in the absence of S9 mix and from 2500 to 5000 µg/plate in the presence of S9 mix. The undissolved particles had no influence on the data recording.

The plates incubated with the test substance showed normal background growth up to the maximal dose of 5000 µg/plate with and without S9 mix in all strains used.

Cytotoxic effects, evident as a reduction in the number of revertants (below the induction factor of 0.5), were observed at the following concentrations (µg/plate):

Strain	Experiment I		Experiment II	
	without S9 mix	with S9 mix	without S9 mix	with S9 mix
TA1535	/	5000	/	/
TA1537	/	/	5000	/
TA98	/	/	2500 – 5000	5000
TA100	/	5000	2500 – 5000	5000
WP2 (pKM101)	5000	/	2500 – 5000	5000
WP2 <i>uvrA</i> (pKM101)	/	/	/	/

/ = no cytotoxic effects, evident as a reduction in the number of revertants (below the induction factor of 0.5)

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N°

Report Number: 2165900

Page 20 of 39

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2° do artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

No substantial increase in revertant colony numbers in any of the six tester strains was observed following treatment with CGA15324/lambda-cyhalothrin EC (A13735F) at any concentration, neither in the presence nor absence of metabolic activation (S9 mix). There was also no tendency of higher mutation rates with increasing concentrations in the range below the generally acknowledged border of biological relevance.

Appropriate reference mutagens were used as positive controls. They showed a distinct increase in induced revertant colonies.

5.0 CONCLUSIONS

In conclusion, it can be stated that during the described mutagenicity tests and under the experimental conditions reported, CGA15324/lambda-cyhalothrin EC (A13735F) did not induce gene mutations by base pair changes or frameshifts in the genome of the strains used.

Therefore, CGA15324/lambda-cyhalothrin EC (A13735F) is considered to be non-mutagenic in the *Salmonella typhimurium* and *Escherichia coli* reverse mutation assay.

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N° 9.609/98, artigo 9° da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2° do artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

6.0 REFERENCES

1. Hollstein, M., J. McCann, F.A. Angelosanto, and W.W. Nichols (1979)
Short-term tests for carcinogens and mutagens
Mutation Res. 65, 133-226
2. Maron, D.M., J. Katzenellenbogen, and B.N. Ames (1981)
Compatibility of organic solvents with the Salmonella/Microsome Test
Mutation Res. 88, 343-350
3. Maron, D.M. and B.N. Ames (1983)
Revised methods for the Salmonella mutagenicity test
Mutation Res. 113, 173-215
4. Green, M.H.L. and W.J. Muriel (1976)
Mutagen Testing Using TRP⁺ Reversion in Escherichia Coli
Mutation Res. 38, 3-32
5. Ames, B.N., J. McCann, and E. Yamasaki (1977)
Methods for detecting carcinogens and mutagens with the Salmonella/mammalian
microsome mutagenicity test
In: B.J. Kilbey et al. (Eds.) "Handbook of Mutagenicity Test Procedures" Elsevier,
Amsterdam, 1-17
6. de Serres, F.J. and M.D. Shelby (1979)
Recommendations on data production and analysis using the Salmonella/microsome
mutagenicity assay
Mutation Res. 64, 159-165
7. Mortelmans, K. and E.S. Riccio (2000)
The bacterial tryptophan reverse mutation assay with Escherichia coli WP2
Mutation Res. 455, 61-69

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo
SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N°
9.279/96, artigo 9° da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles
descritos no parágrafo 2° do artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

TABLES SECTION

CONFIDENTIAL
Property of Syngenta

syngenta®

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo **SEGREDO DE NEGÓCIO** e **SEGREDO DE INDÚSTRIA**, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 10.603/02, artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

TABLE 1 Summary of Results Pre-Experiment/Experiment I

Study Name: 2165900
 Experiment: 2165900 VV Plate
 Assay Conditions:

Study Code: ICCR 2165900
 Date Plated: 05.05.2021
 Date Counted: 10.05.2021

Metabolic Activation	Test Group	Concentration (per plate)	Revertant Colony Counts (Mean ±SD)					
			TA 1535	TA 1537	TA 98	TA 100	WP2 pKM101	WP2 uvrA pKM101
Without Activation	DMSO Untreated		12 ± 4	12 ± 4	29 ± 4	97 ± 9	253 ± 12	328 ± 30
	CGA15324/lambda-cyhalothrin EC (A13735F)	3 µg	12 ± 3	10 ± 2	34 ± 8	105 ± 5	282 ± 4	365 ± 54
		10 µg	13 ± 2	10 ± 3	34 ± 2	110 ± 13	254 ± 14	330 ± 23
		33 µg	10 ± 2	10 ± 4	31 ± 8	104 ± 8	254 ± 17	333 ± 4
		100 µg	13 ± 2	10 ± 4	25 ± 4	88 ± 18	233 ± 36	292 ± 15
		333 µg	11 ± 3	12 ± 2	20 ± 6	80 ± 21	204 ± 17	331 ± 54
		1000 µg	12 ± 4	11 ± 3	24 ± 5	85 ± 13	193 ± 11	283 ± 28
		2500 µg	10 ± 3	13 ± 3	17 ± 4	70 ± 10	142 ± 12	244 ± 16
	5000 µg	14 ± 4 ^P	9 ± 3 ^P	16 ± 5 ^P	54 ± 13 ^{PM}	105 ± 6 ^P	205 ± 13 ^P	
	NaN3	10 µg	1110 ± 37			1793 ± 55		
	4-NOPD	10 µg			436 ± 44			
	4-NOPD	50 µg		62 ± 3				
	MMS	2.0 µL					2333 ± 159	2097 ± 232
With Activation	DMSO Untreated		13 ± 4	11 ± 3	43 ± 2	111 ± 26	274 ± 31	374 ± 20
	CGA15324/lambda-cyhalothrin EC (A13735F)	3 µg	13 ± 3	13 ± 3	47 ± 12	113 ± 13	299 ± 14	422 ± 21
		10 µg	11 ± 2	14 ± 3	34 ± 7	100 ± 2	279 ± 16	416 ± 5
		33 µg	12 ± 3	12 ± 4	40 ± 3	107 ± 9	243 ± 17	391 ± 8
		100 µg	11 ± 1	12 ± 3	40 ± 2	112 ± 12	216 ± 28	364 ± 4
		333 µg	12 ± 4	9 ± 3	33 ± 4	104 ± 6	231 ± 20	352 ± 17
		1000 µg	10 ± 1	14 ± 3	33 ± 8	113 ± 8	249 ± 13	422 ± 24
		2500 µg	10 ± 0	13 ± 3	30 ± 5	79 ± 12	220 ± 17	356 ± 6
	5000 µg	9 ± 1 ^P	16 ± 4 ^P	21 ± 7 ^P	58 ± 8 ^P	185 ± 5 ^P	304 ± 24 ^P	
	2-AA	2.5 µg	5 ± 1 ^P	14 ± 2 ^P	24 ± 4 ^P	41 ± 4 ^{PM}	127 ± 3 ^P	281 ± 31 ^P
	2-AA	10.0 µg	244 ± 4	464 ± 7	2703 ± 182	3676 ± 710	953 ± 33	1334 ± 15

Key to Positive Controls

Key to Plate Postfix Codes

NaN3 sodium azide
 2-AA 2-aminoanthracene
 4-NOPD 4-nitro-o-phenylene-diamine
 MMS methyl methane sulfonate

P Precipitate
 M Manual count

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo **SEGREDO DE NEGÓCIO** e **SEGREDO DE INDÚSTRIA**, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.609/98 e pelo artigo 9º da Lei 10.603/02. É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

TABLE 2 Summary of Results Experiment II

Study Name: 2165900
 Experiment: 2165900 HV2 Pre
 Assay Conditions:

Study Code: ICCR 2165900
 Date Plated: 19.05.2021
 Date Counted: 25.05.2021

Metabolic Activation	Test Group	Concentration (per plate)	Revertant Colony Counts (Mean ±SD)					
			TA 1535	TA 1537	TA 98	TA 100	WP2 pKM101	WP2 uvrA pKM101
Without Activation	DMSO Untreated		10 ± 4	10 ± 1	29 ± 5	95 ± 6	227 ± 21	357 ± 37
	CGA15324/lambda-cyhalothrin EC (A13735F)	10 µg	13 ± 4	10 ± 1	28 ± 9	107 ± 3	289 ± 20	370 ± 3
		33 µg	10 ± 1	12 ± 4	25 ± 5	92 ± 3	194 ± 9	382 ± 66
		100 µg	6 ± 2	9 ± 0	20 ± 3	78 ± 7	160 ± 7	341 ± 24
		333 µg	9 ± 2	10 ± 1	16 ± 6	72 ± 12	109 ± 21	305 ± 8
		1000 µg	6 ± 1	8 ± 3	15 ± 4	79 ± 16	106 ± 21	293 ± 15
		2500 µg	10 ± 3	10 ± 3	12 ± 2	12 ± 1	87 ± 13	222 ± 23
	NaN3	5000 µg	7 ± 1 ^P	3 ± 1 ^{PM}	4 ± 1 ^P	1 ± 1 ^P	45 ± 8 ^P	166 ± 7 ^P
		10 µg	1174 ± 32			1684 ± 110		
	4-NOPD	10 µg			491 ± 4			
		50 µg		83 ± 16				
	MMS	2.0 µL					3287 ± 411	2818 ± 126
With Activation	DMSO Untreated		11 ± 1	16 ± 1	34 ± 5	95 ± 8	248 ± 41	443 ± 38
	CGA15324/lambda-cyhalothrin EC (A13735F)	10 µg	15 ± 4	18 ± 2	40 ± 9	111 ± 6	267 ± 33	405 ± 29
		33 µg	13 ± 3	18 ± 2	34 ± 12	116 ± 14	246 ± 18	528 ± 38
		100 µg	13 ± 3	15 ± 5	32 ± 5	108 ± 13	237 ± 12	437 ± 21
		333 µg	12 ± 4	15 ± 0	33 ± 4	103 ± 10	232 ± 4	408 ± 39
		1000 µg	13 ± 4	14 ± 4	33 ± 6	86 ± 15	198 ± 9	469 ± 21
		2500 µg	10 ± 1	17 ± 2	25 ± 3	65 ± 9	173 ± 31	368 ± 20
	2-AA	5000 µg	10 ± 2 ^P	17 ± 6 ^P	22 ± 1 ^P	49 ± 9 ^{PM}	122 ± 3 ^P	299 ± 33 ^P
		2.5 µg	8 ± 2 ^P	12 ± 4 ^{PM}	12 ± 3 ^{PM}	25 ± 4 ^{PM}	88 ± 5 ^P	233 ± 10 ^P
	2-AA	10.0 µg	231 ± 30	391 ± 13	2136 ± 186	3222 ± 150	954 ± 32	1462 ± 159

Key to Positive Controls

NaN3 sodium azide
 2-AA 2-aminoanthracene
 4-NOPD 4-nitro-o-phenylene-diamine
 MMS methyl methane sulfonate

Key to Plate Postfix Codes

P Precipitate
 M Manual count

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles descritos no parágrafo 2º do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

TABLE 3 Pre-Experiment and Experiment I: 2165900 VV Plate Incorporation Without Metabolic Activation

Study Name: 2165900
 Experiment: 2165900 VV Plate
 Assay Conditions:

Study Code: ICCR 2165900
 Date Plated: 05.05.2021
 Date Counted: 10.05.2021

Without metabolic activation

Strain	Compound	Concentration per plate	Mean revertants per plate	Standard Deviation	Ratio treated / solvent	Individual revertant colony counts
TA 1535	CGA15324/ lambda- cyhalothrin EC (A13735F)	3 µg	11.7	2.9	1.0	10, 15, 10
		10 µg	12.7	2.1	1.1	15, 12, 11
		33 µg	10.3	1.5	0.9	10, 12, 9
		100 µg	13.0	1.7	1.1	12, 12, 15
		333 µg	11.0	2.6	0.9	9, 10, 14
		1000 µg	11.7	3.8	1.0	9, 16, 10
		2500 µg	9.7	2.5	0.8	7, 12, 10
		5000 µg	13.7	4.2	1.1	17 P, 15 P, 9 P
	DMSO		12.0	4.4		14, 7, 15
	Untreated		10.7	4.0		7, 15, 10
TA 1537	CGA15324/ lambda- cyhalothrin EC (A13735F)	3 µg	10.0	1.7	0.8	12, 9, 9
		10 µg	10.0	2.6	0.8	12, 7, 11
		33 µg	10.3	3.5	0.9	14, 7, 10
		100 µg	10.0	3.6	0.8	7, 14, 9
		333 µg	12.0	2.0	1.0	14, 12, 10
		1000 µg	10.7	2.9	0.9	14, 9, 9
		2500 µg	12.7	2.9	1.1	11, 11, 16
		5000 µg	9.3	3.1	0.8	6 P, 12 P, 10 P
	DMSO		12.0	4.4		17, 9, 10
	Untreated		11.7	2.1		11, 14, 10
TA 98	CGA15324/ lambda- cyhalothrin EC (A13735F)	3 µg	33.7	7.6	1.1	27, 32, 42
		10 µg	33.7	2.3	1.1	35, 31, 35
		33 µg	31.3	7.6	1.1	38, 33, 23
		100 µg	24.7	4.0	0.8	27, 27, 20
		333 µg	20.3	6.1	0.7	19, 15, 27
		1000 µg	24.3	4.7	0.8	19, 26, 28
		2500 µg	17.0	4.4	0.6	19, 20, 12
		5000 µg	16.3	5.1	0.6	22 P, 15 P, 12 P
	DMSO		29.3	4.0		30, 33, 25
	Untreated		27.0	1.7		28, 28, 25

Key to Plate Postfix Codes

P Precipitate

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles autorizados pelo artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

Study Name: 2165900
 Experiment: 2165900 VV Plate
 Assay Conditions:

Study Code: ICCR 2165900
 Date Plated: 05.05.2021
 Date Counted: 10.05.2021

Without metabolic activation

Strain	Compound	Concentration per plate	Mean revertants per plate	Standard Deviation	Ratio treated / solvent	Individual revertant colony counts
TA 100	CGA15324/ lambda- cyhalothrin EC (A13735F)	3 µg	105.3	4.5	1.1	110, 105, 101
		10 µg	110.3	13.4	1.1	120, 95, 116
		33 µg	103.7	7.6	1.1	109, 95, 107
		100 µg	87.7	18.2	0.9	91, 68, 104
		333 µg	79.7	20.5	0.8	80, 100, 59
		1000 µg	85.0	13.0	0.9	85, 72, 98
		2500 µg	70.0	9.6	0.7	59, 77, 74
		5000 µg	54.3	13.3	0.6	63 P M, 39 P M, 61 P M
	DMSO		96.7	9.3		94, 89, 107
Untreated		118.3	17.0		101, 119, 135	
WP2 pKM101	CGA15324/ lambda- cyhalothrin EC (A13735F)	3 µg	282.0	3.6	1.1	285, 278, 283
		10 µg	253.7	13.6	1.0	269, 243, 249
		33 µg	254.3	17.1	1.0	274, 246, 243
		100 µg	233.0	36.4	0.9	272, 227, 200
		333 µg	203.7	17.2	0.8	211, 184, 216
		1000 µg	193.3	11.2	0.8	189, 185, 206
		2500 µg	142.0	11.5	0.6	131, 141, 154
		5000 µg	104.7	6.1	0.4	98 P, 106 P, 110 P
	DMSO		253.3	11.5		265, 253, 242
Untreated		291.0	17.3		295, 306, 272	
WP2 uvrA pKM101	CGA15324/ lambda- cyhalothrin EC (A13735F)	3 µg	365.0	54.1	1.1	427, 341, 327
		10 µg	330.0	22.6	1.0	351, 333, 306
		33 µg	333.3	4.2	1.0	332, 338, 330
		100 µg	292.3	15.3	0.9	310, 283, 284
		333 µg	331.0	53.7	1.0	382, 336, 275
		1000 µg	282.7	27.7	0.9	279, 257, 312
		2500 µg	244.0	15.5	0.7	259, 228, 245
		5000 µg	204.7	13.1	0.6	190 P, 215 P, 209 P
	DMSO		328.0	29.6		342, 348, 294
Untreated		380.7	37.1		419, 378, 345	
TA 1535	NaN3	10 µg	1109.7	37.2	92.5	1142, 1118, 1069
TA 1537	4-NOPD	50 µg	62.3	2.9	5.2	59, 64, 64
TA 98	4-NOPD	10 µg	436.3	44.2	14.9	483, 431, 395
TA 100	NaN3	10 µg	1793.0	54.6	18.5	1761, 1856, 1762
WP2 pKM101	MMS	2.0 µL	2333.0	158.8	9.2	2194, 2299, 2506
WP2 uvrA pKM101	MMS	2.0 µL	2097.0	231.8	6.4	1909, 2026, 2356

Key to Positive Controls

NaN3 sodium azide
 4-NOPD 4-nitro-o-phenylene-diamine
 MMS methyl methane sulfonate

Key to Plate Postfix Codes

P Precipitate
 M Manual count

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles especificados no artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

TABLE 4 Pre-Experiment and Experiment I: 2165900 VV Plate Incorporation With Metabolic Activation

Study Name: 2165900
 Experiment: 2165900 VV Plate
 Assay Conditions:

Study Code: ICCR 2165900
 Date Plated: 05.05.2021
 Date Counted: 10.05.2021

With metabolic activation

Strain	Compound	Concentration per plate	Mean revertants per plate	Standard Deviation	Ratio treated / solvent	Individual revertant colony counts
TA 1535	CGA15324/ lambda-cyhalothrin EC (A13735F)	3 µg	10.7	1.5	0.8	9, 11, 12
		10 µg	11.7	2.5	0.9	12, 9, 14
		33 µg	11.3	0.6	0.9	11, 11, 12
		100 µg	12.3	4.0	1.0	10, 17, 10
		333 µg	9.7	0.6	0.8	10, 10, 9
		1000 µg	10.0	0.0	0.8	10, 10, 10
		2500 µg	9.3	0.6	0.7	9 P, 10 P, 9 P
		5000 µg	5.0	1.0	0.4	5 P, 6 P, 4 P
	DMSO		12.7	3.8		10, 17, 11
Untreated		13.3	3.1		10, 16, 14	
TA 1537	CGA15324/ lambda-cyhalothrin EC (A13735F)	3 µg	13.7	2.5	1.2	11, 16, 14
		10 µg	11.7	4.0	1.0	14, 7, 14
		33 µg	12.0	2.6	1.1	15, 10, 11
		100 µg	9.3	2.5	0.8	9, 7, 12
		333 µg	14.3	3.1	1.3	15, 17, 11
		1000 µg	12.7	3.2	1.1	9, 15, 14
		2500 µg	15.7	3.5	1.4	19 P, 16 P, 12 P
		5000 µg	14.0	2.0	1.2	14 P, 12 P, 16 P
	DMSO		11.3	2.5		11, 9, 14
Untreated		12.7	3.1		10, 12, 16	
TA 98	CGA15324/ lambda-cyhalothrin EC (A13735F)	3 µg	33.7	7.4	0.8	31, 28, 42
		10 µg	40.3	3.1	0.9	41, 37, 43
		33 µg	39.7	1.5	0.9	40, 38, 41
		100 µg	32.7	3.8	0.8	37, 30, 31
		333 µg	32.7	8.0	0.8	25, 41, 32
		1000 µg	30.3	4.6	0.7	25, 33, 33
		2500 µg	21.0	7.0	0.5	14 P, 21 P, 28 P
		5000 µg	23.7	4.2	0.6	27 P, 25 P, 19 P
	DMSO		43.0	1.7		41, 44, 44
Untreated		47.3	11.8		40, 61, 41	

Key to Plate Postfix Codes

P Precipitate

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles para os quais foram produzidas, nos termos do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

Study Name: 2165900
 Experiment: 2165900 VV Plate
 Assay Conditions:

Study Code: ICCR 2165900
 Date Plated: 05.05.2021
 Date Counted: 10.05.2021

With metabolic activation

Strain	Compound	Concentration per plate	Mean revertants per plate	Standard Deviation	Ratio treated / solvent	Individual revertant colony counts
TA 100	CGA15324/ lambda- cyhalothrin EC (A13735F)	3 µg	99.7	2.1	0.9	98, 99, 102
		10 µg	107.3	8.5	1.0	107, 116, 99
		33 µg	111.7	11.9	1.0	117, 98, 120
		100 µg	104.3	5.7	0.9	106, 109, 98
		333 µg	113.3	8.0	1.0	105, 121, 114
		1000 µg	79.3	11.5	0.7	68, 79, 91
		2500 µg	58.3	8.1	0.5	62 P, 64 P, 49 P
		5000 µg	41.0	3.6	0.4	44 P M, 37 P M, 42 P M
	DMSO		111.3	25.9		121, 131, 82
	Untreated		113.3	12.7		106, 106, 128
WP2 pKM101	CGA15324/ lambda- cyhalothrin EC (A13735F)	3 µg	279.0	15.5	1.0	278, 264, 295
		10 µg	243.3	16.8	0.9	247, 225, 258
		33 µg	216.0	28.2	0.8	237, 227, 184
		100 µg	231.3	19.5	0.8	209, 240, 245
		333 µg	249.3	13.2	0.9	261, 252, 235
		1000 µg	219.7	16.8	0.8	238, 205, 216
		2500 µg	185.0	5.2	0.7	188 P, 188 P, 179 P
		5000 µg	127.3	2.5	0.5	130 P, 125 P, 127 P
	DMSO		274.0	30.8		282, 300, 240
	Untreated		299.3	13.8		294, 289, 315
WP2 uvrA pKM101	CGA15324/ lambda- cyhalothrin EC (A13735F)	3 µg	416.0	5.3	1.1	422, 412, 414
		10 µg	390.7	8.1	1.0	387, 385, 400
		33 µg	364.0	4.4	1.0	362, 369, 361
		100 µg	352.0	16.5	0.9	369, 336, 351
		333 µg	422.3	23.5	1.1	424, 445, 398
		1000 µg	356.3	6.4	1.0	349, 359, 361
		2500 µg	304.0	24.3	0.8	291 P, 289 P, 332 P
		5000 µg	281.3	31.2	0.8	293 P, 246 P, 305 P
	DMSO		374.3	20.0		375, 354, 394
	Untreated		421.7	21.1		446, 410, 409
TA 1535	2-AA	2.5 µg	244.3	4.2	19.3	249, 241, 243
TA 1537	2-AA	2.5 µg	464.3	6.7	41.0	466, 457, 470
TA 98	2-AA	2.5 µg	2702.7	182.2	62.9	2496, 2772, 2840
TA 100	2-AA	2.5 µg	3676.0	710.2	33.0	4136, 2858, 4034
WP2 pKM101	2-AA	10.0 µg	953.0	33.0	3.5	987, 921, 951
WP2 uvrA pKM101	2-AA	10.0 µg	1334.3	14.6	3.6	1332, 1350, 1321

Key to Positive Controls

2-AA 2-aminoanthracene

Key to Plate Postfix Codes

P Precipitate
 M Manual count

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles para os quais foram originalmente divulgadas, sob pena de aplicação do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

TABLE 5 Experiment II: 2165900 HV2 Pre Incubation Without Metabolic Activation

Study Name: 2165900
 Experiment: 2165900 HV2 Pre
 Assay Conditions:

Study Code: ICCR 2165900
 Date Plated: 19.05.2021
 Date Counted: 25.05.2021

Without metabolic activation						
Strain	Compound	Concentration per plate	Mean revertants per plate	Standard Deviation	Ratio treated / solvent	Individual revertant colony counts
TA 1535	CGA15324/ lambda-cyhalothrin EC (A13735F)	10 µg				
		33 µg	10.0	1.0	1.0	9, 11, 10
		100 µg	6.3	2.3	0.6	9, 5, 5
		333 µg	9.3	2.1	0.9	7, 10, 11
		1000 µg	6.3	0.6	0.6	6, 7, 6
		2500 µg	10.0	2.6	1.0	11, 7, 12
	5000 µg	6.7	0.6	0.7	7 P, 7 P, 6 P	
DMSO		10.0	3.6		14, 7, 9	
Untreated		12.7	3.8		17, 11, 10	
TA 1537	CGA15324/ lambda-cyhalothrin EC (A13735F)	10 µg				
		33 µg	12.3	3.5	1.2	9, 16, 12
		100 µg	9.0	0.0	0.9	9, 9, 9
		333 µg	9.7	0.6	0.9	9, 10, 10
		1000 µg	8.3	3.2	0.8	6, 12, 7
		2500 µg	10.3	2.9	1.0	12, 12, 7
	5000 µg	3.0	1.0	0.3	4 P M, 2 P M, 3 P M	
DMSO		10.3	1.2		11, 11, 9	
Untreated		10.0	1.0		11, 10, 9	
TA 98	CGA15324/ lambda-cyhalothrin EC (A13735F)	10 µg				
		33 µg	25.3	4.9	0.9	31, 23, 22
		100 µg	19.7	3.2	0.7	22, 21, 16
		333 µg	16.3	5.9	0.6	12, 14, 23
		1000 µg	15.3	3.5	0.5	19, 15, 12
		2500 µg	12.3	1.5	0.4	11, 12, 14
	5000 µg	4.3	0.6	0.2	4 P, 4 P, 5 P	
DMSO		28.7	5.1		30, 23, 33	
Untreated		27.7	8.6		20, 26, 37	
TA 100	CGA15324/ lambda-cyhalothrin EC (A13735F)	10 µg				
		33 µg	91.7	3.2	1.0	88, 94, 93
		100 µg	78.0	7.0	0.8	75, 73, 86
		333 µg	72.3	11.9	0.8	86, 64, 67
		1000 µg	79.0	15.9	0.8	61, 91, 85
		2500 µg	11.7	0.6	0.1	12, 11, 12
	5000 µg	1.3	0.6	0.0	2 P, 1 P, 1 P	
DMSO		95.3	5.9		93, 102, 91	
Untreated		106.7	2.5		107, 104, 109	

Key to Plate Postfix Codes

P Precipitate
 M Manual count

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles para os quais foram fornecidas, nos termos do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

Study Name: 2165900
 Experiment: 2165900 HV2 Pre
 Assay Conditions:

Study Code: ICCR 2165900
 Date Plated: 19.05.2021
 Date Counted: 25.05.2021

Without metabolic activation

Strain	Compound	Concentration per plate	Mean revertants per plate	Standard Deviation	Ratio treated / solvent	Individual revertant colony counts
WP2 pKM101	CGA15324/ lambda- cyhalothrin EC (A13735F)	10 µg				
		33 µg	194.0	8.7	0.9	198, 184, 200
		100 µg	159.7	7.4	0.7	154, 157, 168
		333 µg	109.0	21.2	0.5	117, 125, 85
		1000 µg	106.0	21.2	0.5	130, 98, 90
		2500 µg	87.3	13.2	0.4	90, 99, 73
	5000 µg	44.7	7.6	0.2	43 P, 38 P, 53 P	
	DMSO		227.0	21.4		251, 220, 210
	Untreated		289.3	20.3		312, 283, 273
WP2 uvrA pKM101	CGA15324/ lambda- cyhalothrin EC (A13735F)	10 µg				
		33 µg	381.7	66.3	1.1	451, 375, 319
		100 µg	341.3	24.4	1.0	336, 320, 368
		333 µg	304.7	8.1	0.9	296, 312, 306
		1000 µg	293.0	14.7	0.8	306, 296, 277
		2500 µg	222.3	22.7	0.6	248, 214, 205
	5000 µg	166.0	6.6	0.5	172 P, 167 P, 159 P	
	DMSO		356.7	37.1		395, 354, 321
	Untreated		370.0	2.6		373, 369, 368
TA 1535	NaN3	10 µg	1173.7	31.6	117.4	1210, 1153, 1158
TA 1537	4-NOPD	50 µg	83.0	15.6	8.0	73, 101, 75
TA 98	4-NOPD	10 µg	491.3	3.5	17.1	488, 491, 495
TA 100	NaN3	10 µg	1683.7	110.0	17.7	1687, 1792, 1572
WP2 pKM101	MMS	2.0 µL	3286.7	410.7	14.5	3014, 3087, 3759
WP2 uvrA pKM101	MMS	2.0 µL	2818.0	125.6	7.9	2941, 2690, 2823

Key to Positive Controls

NaN3 sodium azide
 4-NOPD 4-nitro-o-phenylene-diamine
 MMS methyl methane sulfonate

Key to Plate Postfix Codes

P Precipitate

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles para os quais foram produzidas, nos termos do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

TABLE 6 Experiment II: 2165900 HV2 Pre Incubation With Metabolic Activation

Study Name: 2165900
 Experiment: 2165900 HV2 Pre
 Assay Conditions:

Study Code: ICCR 2165900
 Date Plated: 19.05.2021
 Date Counted: 25.05.2021

With metabolic activation

Strain	Compound	Concentration per plate	Mean revertants per plate	Standard Deviation	Ratio treated / solvent	Individual revertant colony counts
TA 1535	CGA15324/ lambda-cyhalothrin EC (A13735F)	10 µg	13.3	3.2	1.2	11, 17, 12
		33 µg	13.0	2.6	1.2	16, 12, 11
		100 µg	11.7	3.8	1.1	10, 16, 9
		333 µg	13.0	3.6	1.2	17, 12, 10
		1000 µg	9.7	1.2	0.9	9, 9, 11
		2500 µg	10.3	1.5	0.9	12 P, 10 P, 9 P
		5000 µg	8.0	1.7	0.7	6 P, 9 P, 9 P
	DMSO Untreated		11.0 14.7	1.0 4.0		11, 10, 12 14, 11, 19
TA 1537	CGA15324 /lambda-cyhalothrin EC (A13735F)	10 µg	17.7	2.1	1.1	20, 16, 17
		33 µg	15.0	5.0	0.9	20, 10, 15
		100 µg	15.0	0.0	0.9	15, 15, 15
		333 µg	14.0	3.6	0.9	15, 10, 17
		1000 µg	17.0	2.0	1.0	19, 17, 15
		2500 µg	17.3	5.5	1.1	23 P, 17 P, 12 P
		5000 µg	12.3	3.5	0.8	16 P M, 9 P M, 12 P M
	DMSO Untreated		16.3 17.7	1.2 2.3		17, 17, 15 19, 15, 19
TA 98	CGA15324/ lambda-cyhalothrin EC (A13735F)	10 µg	34.0	12.2	1.0	26, 48, 28
		33 µg	31.7	4.5	0.9	32, 27, 36
		100 µg	33.0	3.6	1.0	37, 32, 30
		333 µg	33.3	5.7	1.0	27, 35, 38
		1000 µg	25.3	2.5	0.7	23, 25, 28
		2500 µg	22.0	1.0	0.6	23 P, 22 P, 21 P
		5000 µg	12.0	3.0	0.4	9 P M, 12 P M, 15 P M
	DMSO Untreated		34.0 39.7	5.3 8.5		30, 32, 40 43, 30, 46
TA 100	CGA15324/ lambda-cyhalothrin EC (A13735F)	10 µg	116.3	14.2	1.2	100, 126, 123
		33 µg	108.3	13.2	1.1	94, 120, 111
		100 µg	103.0	10.1	1.1	114, 94, 101
		333 µg	86.3	15.0	0.9	72, 85, 102
		1000 µg	65.3	8.7	0.7	75, 58, 63
		2500 µg	49.0	8.7	0.5	59 P M, 45 P M, 43 P M
		5000 µg	25.0	4.4	0.3	23 P M, 30 P M, 22 P M
	DMSO Untreated		94.7 111.3	8.4 6.4		85, 100, 99 104, 115, 115

Key to Plate Postfix Codes

P Precipitate
 M Manual count

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles para os quais foram produzidas, nos termos do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

Study Name: 2165900
 Experiment: 2165900 HV2 Pre
 Assay Conditions:

Study Code: ICCR 2165900
 Date Plated: 19.05.2021
 Date Counted: 25.05.2021

With metabolic activation

Strain	Compound	Concentration per plate	Mean revertants per plate	Standard Deviation	Ratio treated / solvent	Individual revertant colony counts
WP2 pKM101	CGA15324/ lambda- cyhalothrin EC (A13735F)	10 µg	245.7	18.0	1.0	263, 247, 227
		33 µg	236.7	11.6	1.0	249, 235, 226
		100 µg	232.3	4.0	0.9	230, 237, 230
		333 µg	198.3	9.0	0.8	199, 189, 207
		1000 µg	172.7	31.2	0.7	146, 207, 165
		2500 µg	121.7	2.9	0.5	120 P, 120 P, 125 P
	5000 µg	88.0	5.2	0.4	94 P, 85 P, 85 P	
	DMSO		248.0	41.0		248, 207, 289
	Untreated		267.3	33.3		278, 230, 294
WP2 uvrA pKM101	CGA15324/ lambda- cyhalothrin EC (A13735F)	10 µg	527.7	38.1	1.2	545, 554, 484
		33 µg	437.3	20.6	1.0	453, 414, 445
		100 µg	408.0	39.1	0.9	382, 453, 389
		333 µg	469.0	20.8	1.1	457, 493, 457
		1000 µg	368.3	19.6	0.8	387, 348, 370
		2500 µg	299.3	32.7	0.7	337 P, 282 P, 279 P
	5000 µg	232.7	10.4	0.5	221 P, 241 P, 236 P	
	DMSO		443.3	38.1		454, 475, 401
	Untreated		404.7	29.5		394, 438, 382
TA 1535	2-AA	2.5 µg	231.0	30.1	21.0	238, 257, 198
TA 1537	2-AA	2.5 µg	391.3	12.5	24.0	391, 404, 379
TA 98	2-AA	2.5 µg	2135.7	186.2	62.8	1934, 2301, 2172
TA 100	2-AA	2.5 µg	3222.3	149.7	34.0	3376, 3214, 3077
WP2	2-AA	10.0 µg	954.3	32.1	3.8	951, 924, 988
pKM101	2-AA	10.0 µg	1462.3	158.6	3.3	1307, 1456, 1624

Key to Positive Controls

2-AA 2-aminoanthracene

Key to Plate Postfix Codes

P Precipitate

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles para os quais foram produzidas, nos termos do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

APPENDICES SECTION

CONFIDENTIAL
Property of Syngenta

syngenta®

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles para os quais foram originalmente concebidas, sob pena de aplicação do artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

APPENDIX 1 Historical Control Data

These data represent the laboratory's historical control data from July 2018 until July 2020 representing approx. 600 experiments (WP2 pKM101, WP2 uvrA pKM101 the historical data are based on approx. 80 experiments).

The positive controls that used to compile the historical positive control data correspond to the positive control substances described in Methods; section 3.2.2 (Positive control substances).

Strain		without S9 mix				with S9 mix			
		Mean	SD	Min	Max	Mean	SD	Min	Max
TA 1535	Solvent control	12	2.6	7	22	13	2.5	7	24
	Untreated control	12	2.9	6	26	13	2.8	7	23
	Positive control	1116	141.3	340	1612	346	72.1	170	736
TA1537	Solvent control	11	2.4	6	20	14	2.8	7	28
	Untreated control	11	2.8	5	22	14	3.2	7	30
	Positive control	83	22.1	48	400	286	98.7	82	630
TA 98	Solvent control	28	4.9	13	46	38	6.4	12	62
	Untreated control	29	5.0	14	48	41	6.8	14	64
	Positive control	421	91.2	216	1218	3275	774.9	322	5699
TA 100	Solvent control	127	30.7	63	214	131	30.0	72	214
	Untreated control	135	35.7	64	233	140	34.4	68	217
	Positive control	1759	273.4	511	2588	3566	837.6	553	5444
WP2 pKM 101	Solvent control	248	31.7	171	299	266	33.0	205	315
	Untreated control	269	26.6	212	346	299	28.2	233	345
	Positive control	3343	428.4	2332	4653	1092	257.8	933	2781
WP2uvrA pKM 101	Solvent control	322	31.6	248	388	375	38.5	287	466
	Untreated control	346	28.2	279	403	393	32.6	313	480
	Positive control	3176	468.5	2021	4717	1897	183.2	1270	2464

Mean = mean value of revertants/plate

SD = standard deviation

Min = minimal value

Max = maximal value

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N° 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles para os quais foram fornecidas, nos termos do artigo 9º da Lei 10.603/02.

APPENDIX 2 Copy of GLP Certificate



Gute Laborpraxis/Good Laboratory Practice

GLP-Bescheinigung/Statement of GLP Compliance

(gemäß/according to § 19b Abs. 1 Chemikaliengesetz)



Eine GLP-Inspektion zur Überwachung der Einhaltung der GLP-Grundsätze gemäß Chemikaliengesetz bzw. Richtlinie 2004/9/EG wurde durchgeführt in

Assessment of conformity with GLP according to Chemikaliengesetz and Directive 2004/9/EEC at:

Prüfeinrichtung/Test facility Prüfstandort/Test site

ICCR-Roßdorf GmbH
Institute for Competent Contract Research
In den Leppsteinswiesen 19
64380 Roßdorf

(Unverwechselbare Bezeichnung und Adresse/Unequivocal name and address)

Prüfungen nach Kategorien/Areas of Expertise

(gemäß/according to ChemVwV-GLP Nr. 5.3/OECD guidance)

2 Prüfungen zur Bestimmung der toxikologischen Eigenschaften
3 Prüfungen zur Bestimmung der erbgutverändernden Eigenschaften (in vitro und in vivo)
8 Analytische Prüfungen an biologischen Materialien

2 Toxicity studies
3 Mutagenicity studies
8 Analytical and clinical chemistry testing

22.11.2018, 21.02.2019, 12. bis 14.03.2019
Datum der Inspektion/Date of Inspection
(Tag Monat Jahr/day month year)

Die genannte Prüfeinrichtung befindet sich im nationalen GLP-Überwachungsverfahren und wird regelmäßig auf Einhaltung der GLP-Grundsätze überwacht.

The above mentioned test facility is included in the national GLP Compliance Programme and is inspected on a regular basis.

Auf der Grundlage des Inspektionsberichtes wird hiermit bestätigt, dass in dieser Prüfeinrichtung die oben genannten Prüfungen unter Einhaltung der GLP-Grundsätze durchgeführt werden können.

Based on the inspection report it can be confirmed, that this test facility is able to conduct the aforementioned studies in compliance with the Principles of GLP.

Im Auftrag

Dr. Astrid Brandt, Referentin, Wiesbaden, den 23. Oktober 2019
(Name und Funktion der verantwortlichen Person/
Name and function of responsible person)



Hessisches Ministerium für Umwelt, Klimaschutz, Landwirtschaft und Verbraucherschutz,
Mainzer Straße 80, D 65189 Wiesbaden
(Name und Adresse der GLP-Überwachungsbehörde/Name and address of the GLP Monitoring Authority)

English name and address of the GLP Monitoring Authority: Hessian Ministry for Environment, Climate Protection, Agriculture and Consumer Protection; Department II 10; P.O. Box 31 09; 65189 Wiesbaden

Translation of seal inscription: Hessian Ministry for Environment, Climate Protection, Agriculture and Consumer Protection

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei Nº 9.279/96 e do parágrafo 2º do artigo 9º da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles autorizados pelo artigo 9º da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

APPENDIX 3 Certificate of S9



CERTIFICATE

ICCR-Roßdorf S9 Preparation Lot No. 291020D

Date of preparation: October 29, 2020

Release date: November 11, 2020

Protein assay: 31.2 mg protein / ml S9

Sterility: 0 colonies / ml S9 on glucose-minimal-agar

Salmonella typhimurium assay (AMES-test)


Treatment	µl S9 / plate	number of revertants in TA 98
negative	0	29
control	100	34
10 µg/plate	0	84
2-Aminoanthracene	100	2898
10 µg/plate	0	30
Benzo(a)pyrene	100	118

The S9 was obtained from the livers of male Wistar rats which received triple treatments of 80 mg / kg body weight Phenobarbital and β-Naphthoflavone orally on consecutive days. The livers were prepared 24 hours after the last treatment.


 Quality Assurance Auditor
 ICCR-Roßdorf GmbH **H. Pilawa**

17. NOV. 2020

Date


 Dr. Steffen Naumann
 Study Director
 ICCR-Roßdorf GmbH

18. NOV. 2020

Date

ICCR-Roßdorf GmbH
 In den Leppsteinswiesen 19, 64380 Roßdorf, Deutschland
 T +49 6154 8070 F +49 6154 83399
 Registergericht Darmstadt, HRB 6837, USt-ID DE812333696
 Geschäftsführer: Dr. Markus Schulz

SOP Origin TS-SOP S9_23

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N° 9.279/96 e do parágrafo 2° do artigo 9° da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles autorizados pelo artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

CERTIFICATE

ICCR-Roßdorf S9 Preparation Lot No. 291020D

Date of preparation: October 29, 2020

Recertification date: May 10, 2021

Protein assay: 31.2 mg protein / ml S9

Sterility: 0 colonies / ml S9 on glucose-minimal-agar


Salmonella typhimurium assay (AMES-test)

Treatment	µl S9 / plate	number of revertants in TA 98	number of revertants in TA 98 (Recertification)
negative	0	29	30
control	100	34	34
10 µg/plate	0	84	86
2-Aminoanthracene	100	2898	1978
10 µg/plate	0	30	25
Benzo(a)pyrene	100	118	106

The S9 was obtained from the livers of male Wistar rats which received triple treatments of 80 mg / kg body weight Phenobarbital and β-Naphthoflavone orally on consecutive days. The livers were prepared 24 hours after the last treatment.

 **Sabine Ebert**
Quality Assurance Auditor
ICCR-Roßdorf GmbH

20. MAI 2021
Date


Dr. Steffen Naumann
Study Director
ICCR-Roßdorf GmbH

20. MAI 2021
Date

ICCR-Roßdorf GmbH
In den Leppsteinswiesen 19, 64380 Roßdorf, Deutschland
T +49 6154 8070 F +49 6154 83399
Registergericht Darmstadt, HRB 6837, USt-ID DE81233696
Geschäftsführer: Dr. Markus Schulz

SOP Origin TS-SOP S9_23

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N° 9.279/96 e do parágrafo 2° do artigo 9° da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles para os quais foram produzidas, sob pena de aplicação do artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

APPENDIX 4 Certificate of Analysis

syngenta

Syngenta Crop Protection AG
GLP Testing Facility WMU
Analytical Development & Product Chemistry
Breitenloh 5
4333 Münchwilen, Switzerland

Certificate of Analysis

A13735F
CGA15324/lambda-cyhalothrin EC (300/015)
SMU1BL001

Batch Identification SMU1BL001
Other Batch ID 1182111
Product Code A13735F
Other Product Code(s) CGA15324/lambda-cyhalothrin EC (300/015)

Chemical Analysis
(Active Ingredient content)

- **Identity of the Active Ingredient(s)*** confirmed
- **Content of profenofos*** 27.3 % w/w corresponding to 300 g/l
- **Content of lambda-cyhalothrin*** 1.37 % w/w corresponding to 15.1 g/l
The Active Ingredient(s) content is within the FAO limits.

Methodology used for Characterization / Recertification. GC, oscillating density meter

Physical Analysis

- **Appearance** brown liquid
- **Density*** 1099 kg/m³

Stability:

- **Storage Temperature** < 30 °C
- **Recertification Date** End of February 2023

If stored under the conditions given above, this test substance can be considered stable until the recertification date is reached.

This Certificate of Analysis summarizes data which originates either from a single study or from several individual studies. Tests marked with an asterisk (*) have been conducted in compliance with GLP.

Raw data, documentation, study plans, any amendments to study plans and reports pertaining to this/these study/studies are stored under the study number(s) referenced below within the archives of the GLP Testing Facility WMU at Syngenta Crop Protection AG, Switzerland.

Study number of batch characterization: CHMU210204
Study number(s) of batch recertification: ---

Authorization: 01 APR 2021



Daniel Jenniches
Analytical Development & Product Chemistry

Page 1 of 1

SEGREDOS INDUSTRIAIS

Estas informações são confidenciais e de propriedade da Syngenta Proteção de Cultivos Ltda., constituindo SEGREDO DE NEGÓCIO e SEGREDO DE INDÚSTRIA, protegidos pelo artigo 195, XI, XII e XIV da Lei N° 9.279/96 e do parágrafo 2° do artigo 9° da Lei 10.603/02.

É terminantemente proibida a divulgação dessas informações e a sua utilização para fins diversos daqueles autorizados pelo artigo 9° da Lei 10.603/02.

Todos os infratores poderão ser processados civil e criminalmente

Report Number: 2165900

Page 39 of 39